Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C14H11F5N2O |
| Molecular Weight | 318.242 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
FC1=C(F)C2=C(NC(=O)N[C@]2(\C=C\C3CC3)C(F)(F)F)C=C1
InChI
InChIKey=JUCDJPCFPITYRP-GFUIURDCSA-N
InChI=1S/C14H11F5N2O/c15-8-3-4-9-10(11(8)16)13(14(17,18)19,21-12(22)20-9)6-5-7-1-2-7/h3-7H,1-2H2,(H2,20,21,22)/b6-5+/t13-/m0/s1
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Expanded-spectrum nonnucleoside reverse transcriptase inhibitors inhibit clinically relevant mutant variants of human immunodeficiency virus type 1. | 1999 Dec |
|
| Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors. | 2000 May 18 |
|
| Potency of nonnucleoside reverse transcriptase inhibitors (NNRTIs) used in combination with other human immunodeficiency virus NNRTIs, NRTIs, or protease inhibitors. | 2002 Jun |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
214287-98-6
Created by
admin on Sat Dec 16 10:16:37 GMT 2023 , Edited by admin on Sat Dec 16 10:16:37 GMT 2023
|
PRIMARY | |||
|
NJZ3VH3QFS
Created by
admin on Sat Dec 16 10:16:37 GMT 2023 , Edited by admin on Sat Dec 16 10:16:37 GMT 2023
|
PRIMARY | |||
|
DPC-082
Created by
admin on Sat Dec 16 10:16:37 GMT 2023 , Edited by admin on Sat Dec 16 10:16:37 GMT 2023
|
PRIMARY | |||
|
6451134
Created by
admin on Sat Dec 16 10:16:37 GMT 2023 , Edited by admin on Sat Dec 16 10:16:37 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
